Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4166/kjg.2019.73.3.121 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Surgical outcomes, survival and prognostic factors in a cohort of lung cancer patients operated at the University of Chile Clinical Hospital.
Medwave
January 2025
Departamento de Cirugía, Hospital Clínico de la Universidad de Chile, Chile.
Introduction: Lung cancer is the leading cause of death by cancer worldwide and has a high lethality. The best treatment for patients with localized disease is anatomical surgical resection, granting good average survival in the long term. We did not find Chilean studies focusing on complications, long term survival or potential association with pathological or clinical factors.
View Article and Find Full Text PDFManagement of head and neck cancer of unknown primary: A phase IV study by DAHANCA.
Eur J Cancer
December 2024
Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark. Electronic address:
Background: Diagnostic and therapeutic management of patients with head and neck squamous cell carcinoma of unknown primary (HNSCCUP) remains a challenge. The aim of the present phase IV study was to assess adherence to the current Danish guidelines and evaluate the treatment outcome in HNSCCUP patients.
Materials And Methods: Prospectively collected data in the DAHANCA database from patients treated between 2014 and 2020 was evaluated.
Predicting early stage lung cancer recurrence and survival from combined tumor motion amplitude and radiomics on free-breathing 4D-CT.
Med Phys
December 2024
Computer and Software Engineering Department, Polytechnique Montréal, Montréal, Quebec, Canada.
Background: Cancer control outcomes of lung cancer are hypothesized to be affected by several confounding factors, including tumor heterogeneity and patient history, which have been hypothesized to mitigate the dose delivery effectiveness when treated with radiation therapy. Providing an accurate predictive model to identify patients at risk would enable tailored follow-up strategies during treatment.
Purpose: Our goal is to demonstrate the added prognostic value of including tumor displacement amplitude in a predictive model that combines clinical features and computed tomography (CT) radiomics for 2-year recurrence and survival in non-small-cell lung cancer (NSCLC) patients treated with curative-intent stereotactic body radiation therapy.
Hepatocellular carcinoma systemic treatment 2024 update: from early to advanced stage.
Biomed J
November 2024
Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan. Electronic address:
Hepatocellular carcinoma (HCC) ranks the sixth most common malignancy but the third leading cause of cancer-related mortality in the world. Significant breakthroughs have been made in systemic treatment for HCC over the past two decades, which have improved treatment outcomes. In addition to multiple tyrosine kinase inhibitors (mTKIs), immune checkpoint inhibitors (ICIs) and antiangiogenic drugs are increasingly being applied.
View Article and Find Full Text PDFOncologic surveillance after surgical treatment for clinically localized kidney cancer: UroCCR study n. 129.
Minerva Urol Nephrol
October 2024
Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France -
Background: In 2021, the EAU Guidelines implemented a novel, expert opinion-based follow-up scheme, with a three-risk-category system for clear cell (cc) and non-cc renal cell carcinoma (non-ccRCC) after surgery with curative intent. We aimed to validate the novel follow-up scheme and provide data-driven recurrence estimates according to risk groups, to confirm or implement the oncologic surveillance strategy.
Methods: We identified 5,320 patients from a prospectively maintained database involving 28 French referral centers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!